177200-76-9

Usage

Uses

Used in Pharmaceutical Industry:
[1-[(Benzyloxy)Methyl]cyclopropyl]Methanol is used as a protected intermediate for the synthesis of Montelukast (M568000), a selective leukotriene D4-receptor antagonist. Montelukast is utilized as an antiasthmatic agent, helping to alleviate the symptoms of asthma by blocking the action of leukotrienes, which are inflammatory mediators that can cause bronchoconstriction and other respiratory issues.

Upstream product

• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 103-63-9 1-phenyl-2-bromoethane 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 100-39-0 benzyl bromide 

Downstream Products

• 1221503-75-8 1-({1-[(benzyloxy)methyl]cyclopropyl}methyl)-4-bromo-5-(4-fluorophenyl)-3-methyl-1H-pyrazole 
• 1346641-23-3 1-((benzyloxy)methyl)cyclopropane-1-carboxylic acid 
• 1380308-82-6 1-({1-[(benzyloxy)methyl]cyclopropyl}methyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1380308-83-7 {1-[(benzyloxy)methyl]cyclopropyl}methyl methanesulfonate 
• 177200-75-8 (((1-(bromomethyl)cyclopropyl)methoxy)methyl)benzene 
• 288401-39-8 1-[(phenylmethoxy)methyl]cyclopropanecarboxaldehyde 
• 288401-41-2 (S)-2-[(1-Benzyloxymethyl-cyclopropyl)-hydroxy-methyl]-3-isopropyl-6,8-dimethyl-nona-6,7-dienoic acid methyl ester 

Relevant academic research and scientific papers

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) or (II): (Formulae (I), (II)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Regioselective dihydropyran formation from 4-iodo-2,6-disubstituted tetrahydropyran derivatives using In(OAc)3/LiI system as the promoter

The rapid and regioselective synthesis of a series of 2,6-disubstituted dihydropyranic building-blocks bearing an oxygenated side chain is described. The corresponding 4-iodo tetrahydropyran precursors, easily prepared by Prins cyclization, underwent regi

Asymmetric total synthesis of (+)-aphanamol I based on the transition metal catalyzed [5 + 2] cycloaddition of allenes and vinylcyclopropanes

(equation presented) A concise asymmetric total synthesis of (+)-aphanamol I is described, based on the transition metal catalyzed [5 + 2] allenyl-vinylcyclopropane cycloaddition. The key cycloaddition precursor is convergently assembled from (R)-(+)-limonene and cyclopropane diester through a novel decarboxylative dehydration reaction. The metal-catalyzed [5 + 2] cycloaddition of this precursor proceeds with complete chemo, endo/exo, and diastereoselectivity in 93% yield, representing an effective general route to bicyclo[5.3.0]decane derivatives.